¿Cómo se compara el ratio PB de MESO con empresas similares?

MESO es un buen valor basado en su ratio Price-To-Book (2.5x) comparado con la media de empresas similares (3.1x).

¿Cómo se compara el ratio PB de MESO con el de otras empresas de la industria US Biotechs ?

MESO es cara en función de su ratio Price-To-Book (2.5x) en comparación con la media de la industria US Biotechs (1.8x).

¿Cuál es el ratio PB de MESO comparado con su ratio PB justo? Este es el ratio PB esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

Datos insuficientes para calcular el ratio justo Price-To-Book de MESO para análisis de valoración.

¿Cuál es el precio justo de MESO si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

MESO ($10.82) cotiza por debajo de nuestra estimación de [[valor justo]] ($167.14)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Mesoblast (Nasdaq:MESO) - Cotización, noticias y análisis

Resumen de acción MESO

Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza. Saber más

Análisis fundamental de MESO
Puntuación del snowflake
Valoración	3/6
Crecimiento futuro	5/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Recompensas

Cotiza un 93.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 61.47%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Mesoblast Limited

Gracell Biotechnologies

NasdaqGS:GRCL

US$990.8m

Arcus Biosciences

NYSE:RCUS

US$1.3b

CareDx

NasdaqGM:CDNA

US$1.2b

Prothena

NasdaqGS:PRTA

US$756.0m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Mesoblast
Precios históricos de las acciones
Precio actual de la acción	AU$10.82
Máximo en las últimas 52 semanas	AU$12.18
Mínimo de 52 semanas	AU$1.61
Beta	2.34
1Cambio en 1 mes	12.12%
Variación en 3 meses	68.27%
Cambio de 1 año	303.73%
3Variación en 3 años	-15.20%
Variación en 5 años	-14.80%
Variación desde la OPV	32.73%

Noticias y actualizaciones recientes

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30

Mesoblast: Rolling The Dice On Cellular Medicines

Jul 22

Recent updates

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Rentabilidad de los accionistas

	MESO	US Biotechs	Mercado US
7D	-7.6%	-7.5%	-1.2%
1Y	303.7%	14.1%	30.4%

Rentabilidad vs. Industria: MESO superó a la industria US Biotechs, que obtuvo un rendimiento del 14.1% el año pasado.

Rentabilidad vs. Mercado: MESO superó al mercado US, que obtuvo un rendimiento del 30.4% el año pasado.

Volatilidad de los precios

Is MESO's price volatile compared to industry and market?
MESO volatility
MESO Average Weekly Movement	11.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: El precio de las acciones de MESO ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MESO ha disminuido de 17% a 11% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2004	73	Silviu Itescu	www.mesoblast.com

Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza. Su plataforma tecnológica patentada de medicina regenerativa se basa en células especializadas conocidas como células de linaje mesenquimal. La empresa ofrece Remestemcel-L, que está en ensayos clínicos de fase III para el tratamiento de enfermedades inflamatorias sistémicas, como la enfermedad aguda de injerto contra huésped refractaria a esteroides y la enfermedad inflamatoria intestinal refractaria a biológicos, así como la enfermedad de Crohn; y Remestemcel-L, que está en ensayos clínicos de fase III para tratar la insuficiencia cardiaca crónica y el dolor lumbar crónico debido a la enfermedad degenerativa del disco.

Resumen de fundamentos de Mesoblast Limited

¿Cómo se comparan los beneficios e ingresos de Mesoblast con su capitalización de mercado?
Estadísticas fundamentales de MESO
Capitalización bursátil	US$1.20b
Beneficios(TTM)	-US$87.96m
Ingresos (TTM)	US$5.90m

202.7x

Ratio precio-ventas (PS)

-13.6x

Ratio precio-beneficio (PE)

¿Está MESO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MESO
Ingresos	US$5.90m
Coste de los ingresos	US$41.07m
Beneficio bruto	-US$35.17m
Otros gastos	US$52.79m
Beneficios	-US$87.96m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.077
Margen bruto	-595.87%
Margen de beneficio neto	-1,490.27%
Ratio deuda/patrimonio	23.8%

¿Cómo se ha desempeñado MESO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción MESO

Recompensas

Análisis de riesgos

Competidores de Mesoblast Limited

NasdaqGS:GRCL

US$990.8m

NYSE:RCUS

US$1.3b

NasdaqGM:CDNA

US$1.2b

NasdaqGS:PRTA

US$756.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L